Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  incomplete Freund's adjuvant
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-11 of 11 for your search:
Start Over
Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 19 to 90
Sponsor: Other
Protocol IDs: SuMo-Sec-01, PEI 0899/01, IRB 07/03, NCT00108875
Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 2006-003619-29, NCT01272466
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 15931, MEL60, NCT02126579
Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0289, HRPO Log Number A-15872, NCI-2010-02375, W81XWH-10-1-0699, NCT01890980
Safety of Peptide Vaccination for Patients with Myelodysplastic Syndrome
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: NHLBI
Protocol IDs: 060062, 06-H-0062, NHLBI-06-H-0062, NCT00270452
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 20 to 80
Sponsor: Other
Protocol IDs: TPR07-079, NCT00632333
Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 20 to 85
Sponsor: Other
Protocol IDs: SUMS-21-72, UMIN000003189, NCT01069575
Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: SUMS-21-74, UMIN000003191, NCT01069653
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2012-004, NCT01810016
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBMPI03-Hem-01, NCT02240537
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: I 247913, NCI-2014-02621, P30CA016056, NCT02334865
Start Over